Form 8-K Unicycive Therapeutics, For: May 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Noble Capital Reiterates Outperform Rating on Unicycive Therapeutics (UNCY)
May 14, 2024 8:44 AM EDTNoble Capital analyst Robert LeBoyer reiterated an Outperform rating and $6.00 price target on Unicycive Therapeutics (NASDAQ: UNCY).
The analyst comments "We Believe OLC Will Have Advantages Over Other Phosphate Binding Drugs.
OLC was formulated to reduce pill burden and improve compliance in... More
